Univest
Univest
  • Markets

Akums Drugs and Pharmaceuticals Q4 FY26 Results: PAT of Rs 87.40 crore Contract Manufacturing – Pharma CDMO

  • May 15, 2026
  • Posted by: Neeraj Pandey
  • Category: News
No Comments
Akums Drugs and Pharmaceuticals Q4 FY26 Results

Akums Drugs and Pharmaceuticals Q4 results were announced on May 14, 2026, at the company’s board meeting. the company Reported profit was Rs 87.40 crore. India’s largest contract pharmaceutical manufacturer provides formulation development and manufacturing services to domestic and multinational pharmaceutical companies. Investors tracking the company will find complete financial data, analysis, and FY27 outlook in this article.

Click Here – Get Free Investment Predictions

Table of Contents

Toggle
  • Akums Drugs and Pharmaceuticals Q4 FY26 Key Financial Highlights
  • Akums Drugs and Pharmaceuticals Performance Analysis
  • Akums Drugs and Pharmaceuticals FY27 Outlook
  • Frequently Asked Questions on Akums Drugs and Pharmaceuticals Q4 FY26 Results
    • What is it PAT?
    • When did Akums Drugs and Pharmaceuticals announce Q4 FY26 results?
    • What is the FY27 outlook for Akums Drugs and Pharmaceuticals?
    • Where can I track the company live data?

Akums Drugs and Pharmaceuticals Q4 FY26 Key Financial Highlights

Metric Q4 FY26 Comparison
PAT (Net Profit) Rs 87.40 crore Q4 FY25 / Reference
Ticker AKUMS Sector: Contract Manufacturing – Pharma CDMO

Screen the best stocks on the Univest Screener.

Akums Drugs and Pharmaceuticals Performance Analysis

The company results reflect the company’s operational performance during the January to March 2026 quarter. the company Reported profit was Rs 87.40 crore. India’s largest contract pharmaceutical manufacturer provides formulation development and manufacturing services to dome Investors and analysts monitoring the company results will focus on FY27 revenue guidance, margin trajectory, and management commentary on business outlook.

The company performance positions the company for FY27. Track the company analyst ratings and live stock price on the Univest Screener for real-time investment insights.

Akums Drugs and Pharmaceuticals FY27 Outlook

Post Akums, investor focus for FY27 will be on revenue growth momentum, margin expansion, new order wins, and sector-specific tailwinds in the Contract Manufacturing – Pharma CDMO space. The Akums results demonstrate the company’s execution capabilities. Track Akums updates on the Univest Screener for analyst views and FY27 earnings estimates.

Download the Univest iOS App or the Univest Android App to track live price and Q4 FY26 earnings updates.

Frequently Asked Questions on Akums Drugs and Pharmaceuticals Q4 FY26 Results

What is it PAT?

Ans. Akums profit after tax was Rs 87.40 crore.

When did Akums Drugs and Pharmaceuticals announce Q4 FY26 results?

Ans. the company results were announced on May 14, 2026, at the company’s board meeting and filed with BSE and NSE.

What is the FY27 outlook for Akums Drugs and Pharmaceuticals?

Ans. Post the company results, investors will track FY27 guidance and growth strategies in the Contract Manufacturing – Pharma CDMO sector. Track live updates on the Univest Screener.

Where can I track the company live data?

Ans. Track the company live stock price, analyst ratings, and earnings updates on the Univest Screener for real-time investment data.

Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Consult a SEBI-registered advisor before making any investment decision.



News Q4 Results
Author: Neeraj Pandey
Neeraj Pandey is a Financial Content Writer at Univest, covering Indian equity markets with a specialisation in quarterly earnings previews and analyst consensus analysis. His published work tracks Q4 FY26 results across 10+ sectors — from IT heavyweights like Infosys and TCS to PSUs like Coal India and Balmer Lawrie, and mid-caps like Neuland Laboratories, MCX, and Whirlpool of India. His writing approach is data-first: every article anchors on NSE/BSE filings, analyst consensus estimates (revenue, PAT, EBITDA margins), 52-week price context, and YoY/QoQ comparisons — giving retail investors the same structured framework institutional desks use before an earnings event. He combines SEO-optimised structure with rigorous data sourcing, ensuring each preview ranks for investor search intent while meeting SEBI editorial standards. All articles are reviewed by Univest's in-house equity research team, led by Ankit Jaiswal, Senior Equity Research Analyst, to meet SEBI editorial standards.

Leave a Reply Cancel reply